HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.

AbstractOBJECTIVES:
To evaluate clinical utility of trisulfated-heparin disaccharide (TS-HDS) IgM testing from real-world tertiary care center experience.
METHODS:
Medical records of patients with positive TS-HDS antibodies who were evaluated at Mayo Clinic from 2009 to 2022 were reviewed.
RESULTS:
Seventy-seven patients (50 females) had positive TS-HDS antibody. Median age was 48 (9-77) years. Median titer was 25,000 (range 11,000-350,000). Twenty-six patients (34%) did not have objective evidence of peripheral neuropathy. Nine patients (12%) had other known causes of neuropathy. Among the remaining 42 patients, half presented with subacute progressive course; the other half had chronic indolent course. Most common phenotypes were length-dependent peripheral neuropathy (n = 20, 48%), length-dependent small-fiber neuropathy (n = 11, 26%), and non-length-dependent small-fiber neuropathy (n = 7, 17%). Nerve biopsies showed epineurial inflammatory cell collections in 2 but no interstitial abnormalities in the remaining 7. The majority of intraepidermal nerve fiber densities (7/10), thermoregulatory sweat tests (12/21) and autonomic reflex screens (27/49) were normal. Post-immunotherapy improvement in mRS/INCAT disability score/pain was only seen in 13/42 (31%) TS-HDS IgM positive patients. Patients presenting with sensory ganglionopathy, non-length dependent small-fiber neuropathy, or subacute progressive neuropathy with and without TS-HDS antibody responded similarly to immunotherapy (40% vs 80%, p = 0.30).
DISCUSSION:
TS-HDS IgM has limited phenotypic or disease specificity; it was found to be positive among patients with various neuropathy phenotypes as well as patients without objective evidence of neuropathy. Clinical improvement with immunotherapy, although was observed in a small proportion of TS-HDS IgM seropositive patients, was not more frequent when compared to seronegative patients with similar presentations.
AuthorsPitcha Chompoopong, Mohamed Rezk, Igal Mirman, Sarah E Berini, P James B Dyck, Michelle Mauermann, Kamal Shouman, Christopher Klein, John R Mills, Divyanshu Dubey
JournalJournal of neurology (J Neurol) Vol. 270 Issue 9 Pg. 4523-4528 (Sep 2023) ISSN: 1432-1459 [Electronic] Germany
PMID37294321 (Publication Type: Journal Article)
Copyright© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Chemical References
  • heparin disaccharide
  • Autoantibodies
  • Immunoglobulin M
Topics
  • Female
  • Humans
  • Middle Aged
  • Autoantibodies
  • Tertiary Care Centers
  • Peripheral Nervous System Diseases (diagnosis, pathology)
  • Small Fiber Neuropathy
  • Immunoglobulin M

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: